secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0001104659-23-126599
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara discontinues AD program after oral difelikefalin fails Phase 3 KIND 1 study
--------------------------------------------------------------------------------

- Oral difelikefalin as adjunct to TCS did not meet primary endpoint vs TCS alone in 287-patient trial.
- Cara discontinues clinical program for pruritus in atopic dermatitis.
- Late-stage programs for notalgia paresthetica and advanced CKD continue; data readouts expected 2H24.
- Cara expects ~$100M cash at year-end 2023, including $20M milestone payment from HealthCare Royalty.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/0001104659-23-126599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923126599/tm2333104d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-126599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer